Gene expression analysis of the hepatotoxicant methapyrilene in primary rat hepatocytes: an interlaboratory study.

Genomics technologies are used in several disciplines, including toxicology. However, these technologies are relatively new, and their applications require further investigations. When investigators apply these technologies to in vitro experiments, two major issues need to be clarified: a) can in vitro toxicity studies, in combination with genomics analyses, be used to predict the toxicity of a compound; and b) are the generated toxicogenomics data reproducible between laboratories? These questions were addressed by an interlaboratory study with laboratories of four pharmaceutical companies. We evaluated gene expression patterns from cultured rat primary hepatocytes after a 24-hr incubation with methapyrilene (MP). Extensive data analysis showed that comparison of genomics data from different sources is complex because both experimental and statistical variability are important confounding factors. However, appropriate statistical tools allowed us to use gene expression profiles to distinguish high-dose-treated cells from vehicle-treated cells. Moreover, we correctly identified MP in an independently generated in vitro database, underlining that in vitro toxicogenomics could be a predictive tool for toxicity. From a mechanistic point of view, despite the observed site-to-site variability, there was good concordance regarding the affected biologic processes. Several subsets of regulated genes were obtained by analyzing the data sets with one method or using different statistical analysis methods. The identified genes are involved in cellular processes that are associated to the exposure of primary hepatocytes to MP. Whether they are specific for MP and are cause or consequence of the toxicity requires further investigations. Key words: hepatotoxicity, interlaboratory study, methapyrilene, microarray, rat hepatocytes, toxicogenomics. Environ Health Perspect 114:92-99 (2006). doi: 10.1289/ehp.7915 available via http://dx.doi.org/[Online 12 August 2005]

**********

In the last decade, genomic technologies have become gradually integrated into several phases of drug development. In the field of toxicology, drug safety laboratories have begun to use these technologies to assist research to conduct toxicity evaluations on as many potential lead compounds as feasible and to gain a better understanding of the mechanisms of toxicities. For investigators to be successful in the selection of compounds most likely to succeed during preclinical development, the methods they use should have a medium throughput, a short turnaround time, a good predictivity, and be reproducible.

In vitro systems are being used in toxicology studies to determine several kinds of toxicities. Mouse lymphoma cells, primary rat hepatocytes, and human lymphocytes are among the mammalian cell systems used to determine mutagenicity (Kilbey et al. 1984). Primary rat or human hepatocytes are used to determine cytotoxicity as well as metabolism of compounds or their ability to induce cytochrome P450 genes (Gomez-Lechon et al. 1988; Paillard et al. 1999). However, only a few laboratories have investigated whether in vitro systems can be used in the toxicogenomics evaluation of development compounds. Harries et al. (2001) used the human liver HepG2 cell line to investigate gene expression changes of two hepatotoxins. The results strongly suggested that different mechanisms of hepatotoxicity may be associated with specific markers of gene expression. Waring et al. (2001) showed that gene expression profiles for compounds with similar mechanisms of toxicity tested in vitro on primary rat hepatocytes formed clusters, suggesting a similar effect on transcription. Conversely, Boess et al. (2003) characterized several hepatic in vitro systems on the basis of gene expression profiling and concluded that the results were poorly comparable with the in vivo outcome, depending on the cell culture system used. It is therefore essential to obtain more knowledge on the in vitro system used to achieve better understanding and interpretation of genomics data.

As genomics technologies have been introduced more and more in toxicology, the International Life Sciences Institute Health and Environmental Sciences Institute (ILSI/ HESI) has formed a consortium with more than 30 pharmaceutical companies to address the issues of reliability and reproducibility of these assays (Robinson et al. 2003). Within the ILSI/HESI consortium, the hepatotoxicity working group evaluated the two hepatotoxicants methapyrilene (MP) and clofibrate by gene expression analysis of rat livers (Baker et al. 2004; Chu et al. 2004; Hamadeh et al. 2002; Pennie et al. 2004; Ulrich et al. 2004; Waring et al. 2004). The results of these studies showed that the transferability of microarray technologies between laboratories posed serious protocol-related issues that could be solved only with appropriate and sophisticated statistical tools (Waring et al. 2004).

In the present study, a toxicogenomics experiment using primary rat hepatocytes was performed in the laboratories of four pharmaceutical companies: Bayer HealthCare AG (BA), Boehringer Ingelheim Pharma GmbH & Co. KG (BI), F. Hoffmann-La Roche Ltd. (RO), and Schering AG (SAG). The cell cultures were exposed to two concentrations of MP, an H1 histamine receptor antagonist (Noguchi et al. 1992) that is known to cause periportal cell necrosis (Steinmetz et al. 1988) and liver tumors in rats (Liijnski et al. 1980; Mirsalis 1987). The study was designed to assess the biologic and experimental variability of the in vitro systems of the laboratories, to compare their statistical analysis strategies, and to determine whether an in vitro toxicogenomics experiment, performed in different laboratories from cell culture to data analysis, would identify a toxic compound with the same reliability.

To reduce the experimental variability, a cell culture protocol with a standardization of the main parameters such as culture medium was used. However, many steps, including perfusion and RNA isolation, followed the individual in-house protocols. Each laboratory performed Affymetrix gene expression analysis on the RG-U34A chip and analyzed the data according to its own methods/software.

Materials and Methods

Test article and formulation. Methapyrilene hydrochloride (CAS no. 135-23-9, lot no. 037F0929) was obtained from Sigma Chemical Corp. (St. Louis, MO, USA). MP was formulated in dimethyl sulfoxide (DMSO).

Primary rat hepatocytes. Primary rat hepatocytes were isolated from 10- to 12-week-old male Han:WIST rats (200-300 g body weight; SAG: Tierzucht Schoenwalde GmbH, Schoenwalde, Germany; BA: Harlan Winkelmann, Borchen, Germany; BI: Charles River Deutschland GmbH, Sulzfeld, Germany; RO: RCC Ltd., Itingen, Schweiz) by a two-step collagenase liver perfusion method (Seglen 1972). After perfusion the liver was excised and the cells were resuspended in William's E medium (WME) without phenol red and filtered. Dead cells were removed by a Percoll (Sigma) centrifugation step (Percoll density, 1.06 g/mL, 50 g, 10 min; only at RO and SAG). Primary hepatocyte viability was assessed by trypan blue exclusion and ranged between 72 and 92% (Table 1).

Cells were cultured in six-well plates coated with collagen (Menal GmbH, Herbolzheim, Germany) at a density of [10.sup.6] cells/well in 2 mL WME supplemented with 10% fetal calf serum (Invitrogen Technologies, Paisley, UK), glutamine (2 mM), hydrocortisone (54 ng/mL), glucagon (7 ng/mL), insulin (5 [micro]g/mL), penicillin (100 U/mL), streptomycin (100 mg/mL), and gentamicin (10 [micro]g/mL) at 37[degrees]C in an atmosphere of 5% C[O.sub.2]/95% air. After an attachment period of 3 hr, the medium was replaced by 2 mL serum-free WME, with the same supplements.

Treatment conditions. To determine the concentration of MP that causes a toxic response in hepatocytes, each laboratory performed two-dose finding studies. After an overnight preculture period of 16-18 hr, the cells were treated with MP, 0-300 [micro]M (BA and RO), and 0-1,000 [micro]M (BI and SAG) in 0.2% DMSO (final concentration) or vehicle (0.2% DMSO, final concentration). The same procedure was performed for the main study, using the two selected concentrations.

Biochemistry. Cytotoxicity was determined as lactate dehydrogenase (LDH) release into the cell culture medium. LDH activity was determined spectrophotometrically with commercially available test kits (Table 1). Enzyme activity in the medium was determined and expressed as percentage of LDH activty present in the medium of vehicle-treated cells.

RNA isolation. Cells were harvested at 24 hr after treatment either in Qiagen lysis buffer (RNeasy mini kits; Qiagen, Hilden, Germany) without (BA and SAG) or with proteinase K (BI) or in RNAzol/Biol 01 (RO) (RNAzol: Tel-Test, Inc., Friendswood, TX, USA; Bio101: Buena Vista, CA, USA). Total RNA was isolated using Qiagen RNeasy columns. The quality of the RNA was determined using the Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Amounts of RNA were determined with RiboGreen (Molecular Probes, Leiden, the Netherlands) or by O[D.sub.260]/O[D.sub.280] determination.

DNA microarray analysis. Processing of RNA and microarray experiments were carried out basically as recommended by Affymetrix (Affymetrix, Inc., High Wycombe, UK) (Lockhart et al. 1996), with some user-specific variations (Table 1). Labeled in vitro transcripts (10-20 [micro]g) for each RNA sample were hybridized on the RG-U34A array. A starting amount of 5-20 lag total RNA was used for the synthesis of double-stranded cDNA with a commercially available kit (Superscript Choice System; Invitrogen Life Technologies) in the presence of a T7-[(dT).sub.24] DNA oligonucleotide primer. The cDNA was purified by phenol/chloroform/isoamyl alcohol extraction and ethanol precipitation or using the Affymetrix cleanup columns. The purified cDNA was then transcribed in vitro (Enzo Diagnostics, Inc., Farmingdale, NY, USA; Ambion, Inc., Austin, TX, USA) in the presence of biotinylated ribonucleotides to form biotin-labeled cRNA. The labeled cRNA was purified on an affinity resin (RNeasy, Qiagen, or Affymetrix cleanup), quantified, and fragmented. Labeled cRNA (10-20 [micro]g) was hybridized for approximately 16 hr at 45[degrees]C onto the RG-U34A array. The arrays were washed and stained with streptavidin-R-phycoerythrin (SAPE, Molecular Probes, CA, USA), and the signal was amplified using a biotinylated goat anti-streptavidin anti-body (Vector Laboratories, Burlingame, CA, USA) followed by a final staining with SAPE. Arrays were stained using the GeneChip Fluidics Workstation 400 (Affymetrix). The arrays were then scanned using a confocal laser scanner (GeneArray Scanner 2500; Hewlett Packard, Palo Alto, CA, USA, or Agilent Technologies) resulting in an image file (*.DAT file). Using the Affymetrix software, *.CEL files were calculated from the image files.

Dam analysis. The *.DAT and *.CEL files were distributed among the participants. The data were condensed and normalized (Table 1). The individual analysis strategy of the raw data is described below.

Investigators at BA identified the genes that are regulated to a statistically significant extent by performing a t-test (Welch's modification; Welch 1938) between the control group and each of the treatment groups using Expressionist software (GeneData, Basel, Switzerland). A p-value of 0.01 was chosen in conjunction with a 1.5-fold change cutoff.

Investigators at BI, in addition to the values derived from Microarray Analysis Software (MAS, version 5.0; Affymetrix), performed analysis calculations using the Statistical Analysis System (SAS) software (version 6.12; SAS Institute, Cary, NC, USA). To extract differential expressed genes, the following cutoff criteria were defined. The extracted genes must have a p-value of 0.05 (one-sided) according to the Mann-Whitney U-test. In addition, each probe set (gene) with a fold change value of at least 1.2 was selected. This approach was used as a first filter (and not considered statistically significant). The generated data can then be analyzed by using in-house marker genes [selected in earlier studies of a licensed database (DB)] or in-depth analysis of single selected genes.

Investigators at RO compared treated and control groups and statistical analyses were performed with in-house developed software. Gene expression changes are measured by the Affymetrix software as fluorescence intensities with a given signal (numerical value) and a qualifier or call (present, absent, marginal). If probe sets are detected as expressed, the call is set to 1; if the probe set is absent, this value is set to 0, and if marginal to 0.5. To allow comparability between microarrays, the signal is scaled using the mean intensity of all probe sets on a chip. The numerical values for several replicates are condensed by using the mean and the SD. Differences in expression levels are expressed as change factors (CHGF), which report the change in expression (signal) between two experimental conditions (baseline = control and treated). If an increase is seen, CHGF is calculated as [(signal treated/signal control) - 1]; for a decrease it is [- (signal control/signal treated) + 1]. Thus, the data are symmetrically distributed around 0; a 2-fold increase gives a CHGF of 1, whereas a 50% reduction gives a CHGF of -1. Statistical analysis was based on analysis of variance and Student's t-test. Gene probes considered "expressed" in 50% of the samples (call [greater than or equal to] 0.5) and showing fold changes > 1.25 or < -1.25 with a significance value of at least 0.1 (paired t-test) in one of the individual data sets were selected.

Investigators at SAG, compared treated and control groups, and statistical analyses were performed with Expressionist software.

To extract differentially expressed genes, a t-test was used. Genes with a p-value < 0.01 and a fold change > 1.5 were extracted from every participant's experiment set of three.

Comparison with an in vitro toxico-genomics database. The data sets processed by RO were compared with the Roche proprietary in vitro toxicogenomics DB consisting of 17 compounds that had been tested previously in at least two concentrations. These compounds were tested following Roche-specific cell culture protocols, which were similar but not identical to the protocol described here. Among them was a previous experiment with MP on rat primary hepatocytes at two concentrations (MP_DB; 100 and 300 [micro]M). The comparisons are based on the individual gene expression ratios (fold changes).

Results

Biochemistry. In a pilot study the four different laboratories performed a cell culture experiment by incubating primary rat hepatocytes with several concentrations of MP (0-1,000 [micro]M) and analyzing liver enzyme (LDH) release into the medium 24 hr after treatment. Of the four companies, three showed a slight but significant increase of LDH release into the medium at a concentration of 100 [micro]M MP, whereas at a lower dose (20 [micro]M) there was no enhanced LDH leakage compared with untreated cultures (Figure 1A). On the basis of this result, investigators chose a high dose of 100 [micro]M and a low dose of 20 [micro]M for the toxicogenomics experiments.

As anticipated from the results of the pilot experiments, a tendency toward increased LDH release was seen after 24-hr treatment with 100 [micro]M MP during the toxicogenomics experiment (Figure 1B). However, in agreement with the pilot experiment (Figure 1A), this was not seen in all companies. It is important to note that the absolute values of LDH release in the vehicle controls varied considerably between the individual repeats within as well as between the companies, depending on the respective batch of freshly isolated hepatocytes and the different methodologies used to measure the LDH. Therefore, the results were expressed as percentage of LDH release in vehicle-treated cells.

Gene expression--comparisons across users. In the toxicogenomics experiment rat primary hepatocytes were incubated with 0, 20, or 100 [micro]M of MP for 24 hr and analyzed for gene expression responses using Affymetrix GeneChips. The raw data (*.CEL and *.DAT files) were exchanged among the participants of this study for individual analysis.

Analysis of all data sets with one method. All data sets were analyzed following the analysis strategy from SAG. First, to obtain a general overview of similarities among experimental data sets, a one-dimensional hierarchical clustering (Figure 2) was performed on all data sets. This analysis shows that the data sets cluster together according to their origin. The differences in the gene expression responses are greater between different laboratories than between treated and control hepatocytes.

In the next round of analyses, SAG identified differentially regulated probe sets for each of the participating laboratories (t-test with p < 0.01 plus fold change > 1.5). This approach eliminates the variability caused by different analysis strategies and reveals the variability due to hepatocyte culture and chip processing protocols. In all studies a substantial increase in regulated probe sets is seen when the MP dose is increased (data not shown). The data set generated from the BI study appeared to have significantly more differentially regulated probe sets at the low dose compared with the other laboratories, whereas the data set of SAG showed the fewest changed probe sets at the high dose. The union of all differentially expressed probe sets results in a number of 744. The overlapping number of probe sets detected as regulated in the experiments of all four users was only five and in at least three of four experiments was 46 (data not shown). The highest concordance between two companies, defined as percentage of "own" genes shared with another company, was 34% (data not shown). When using all 744 probe sets detected as regulated in a principal component analysis (PCA), a distinct separation can be achieved between the untreated samples and those treated with the high-dose MP (Figure 3A). This is in good agreement with the biochemistry data, which showed that slight cytotoxicity was observed at the highest dose of MP, at least by most of the companies. The low-dose samples do not separate well from the untreated for all laboratories. This low dose was chosen as a dose that would not show toxicity based on LDH release. The data show that PC1 (accounting for 15.4% of the variance) drives the treatment-related differences as indicated by the arrows, whereas PC2 (accounting for 8.9% of the variance) shows a separation of the individual laboratories.

The same group of probe sets was used in an unsupervised clustering method, hierarchical clustering. The dendrogram (Figure 3B) shows a clustering of the low-dose samples with their untreated counterparts as well as a clustering of the high-dose samples. The only exception is one of the low-dose samples of BI that clusters together with the high-dose sample of the same experiment.

Analysis of one data set with different methods. The four laboratories used very different analysis approaches with different main objectives (described in "Materials and Methods" and Table 2). To evaluate the differences of the resulting gene lists generated by the analysis method, the four participating laboratories analyzed one data set (*.DAT or *.CEL files provided by BI) according to their own standard methods. The methods used basically selected genes according to p-values from a given statistical test and fold changes (Table 2). RO and BI used a relatively low stringency to select a high number of differentially regulated genes, which then can be compared with their gene expression DB to search for similarities with known toxic compounds. BA and SAG used methods with a higher stringency to obtain gene lists with a low number of false positives. The resulting genes are then annotated and assigned to pathways to determine their biologic significance with respect to the mechanism of toxicity of the investigated compound. Table 2 lists the number of genes found with each method, and Figure 4 displays a Venn diagram depicting the number of genes shared between the different analysis methods. As expected, the different analysis strategies have an immense impact on the number of genes that are defined as differentially regulated. A total of 111 genes were detected with all four methods, whereas three of four methods detected an additional 194 genes (i.e., at least three of four methods detected 305 genes).

Analysis of each data set with individual methods. Each laboratory analyzed its own data set using the specific methods as described in "Materials and Methods." The resulting lists of differentially expressed genes are given in Table 3. Again, as expected, more stringent criteria used by BA and SAG detected only 126 and 185 probe sets as changed, respectively; whereas BI and RO obtained 2,486 and 1,085 probe sets, respectively. Comparison of the gene lists resulting from these analyses shows that BA and SAG share 45% or more of their changed probe sets with BI and RO but only 9-16% with each other. The Venn diagram in Figure 5 shows the relation between the different gene lists. Fourteen genes were detected as regulated by all companies, and an additional 103 genes by three of four companies. The identity of the regulated genes as well as the affected cellular pathways and their biologic significance were determined (Table 4). The probe sets consistently detected by all involved users are associated with detoxification, mitochondrial function, energy production, cell stress, and many general housekeeping processes.

Comparison with a gene expression data-base. The gene expression profiles of the high-and low-dose MP from the experiments performed in the individual companies (*.DAT files) and analyzed with the strategy of RO were compared with the Roche in vitro toxicogenomics DB. At the time of analysis, this proprietary DB contained 47 data sets from 17 different hepatotoxic compounds. The comparison revealed that the high-dose data of each company, except those of SAG, fitted best to the Roche MP data, which were generated in a previous, independent experiment (Table 5). The high dose of SAG and the low doses of all companies were more difficult to predict. When the data sets of this study were incorporated in the DB, the MP data from each company always fitt best to the data from this experiment of the other companies. In most cases, this was also true for the low-dose experiments (Table 5).

Discussion

The aim of this multisite experiment was to obtain an estimate of lab-to-lab variability for in vitro gene expression analysis and to determine whether an in vitro toxicogenomics experiment performed in different laboratories from cell culture to data analysis would identify a toxic compound with the same reliability. The toxicogenomics in vitro approach shows the known advantages of other in vitro test systems, namely, the reduction of the number of animals used for biologic assays as well as the time involved and the cost of the assays. For this investigation, we selected the well-known nongenotoxic hepatocarcinogen MP, which had earlier been chosen as a model hepatotoxin within the ILSI/HESI consortium. To comply with minimal statistical requirements (Lee et al. 2000), each experiment was performed in triplicate using three different batches of primary rat hepatocytes. The number of replicates required to achieve the necessary statistical power was not addressed in this work. Although the main cell culture conditions were standardized, slight differences were already observed when comparing the cytotoxicity of various concentrations of MP during the pilot studies performed to define suitable concentrations. Although increased LDH release was observed with concentrations of 100 [micro]M MP and above in three of the four companies, no increased LDH leakage was observed by BA with concentrations up to 300 [micro]M in a pilot experiment (Figure 1A). The reason for this was not investigated further, and concentrations that caused only marginal or no LDH release were chosen for the main experiment (20 and 100 [micro]M).

Analysis of the gene expression data with one-dimensional hierarchical clustering using the whole set of genes available on the RG-U34A GeneChip revealed that the differences between laboratories were greater than the differences between treatment groups. This was not surprising, as it has already been observed in an interlaboratory analysis reported by Waring et al. (2004). However, when focusing on the statistically significant gene expression changes from the data sets of all laboratories (genes were obtained by using the statistical methods of laboratory SAG: t-test, p < 0.01, fold change > 1.5), the clustering results reflected the experimental design, allowing the high-concentration samples to be separated from the controls and low-dose samples (Figure 3B). In addition the hepatocyte cultures of BA and BI appeared to be more sensitive to MP treatment than those of RO and SAG because PCA showed the separation of the low dose from the untreated for BA and BI. This might be because RO and SAG perform a Percoll gradient to separate the live hepatocytes from dead cells. This also removes other cell types from the preparation and might affect the sensitivity of the test system. Thus, using a suitable statistical method, the effect of the treatment supersedes the experimental variability. Differences on the experimental systems such as cell preparation (Percoll purification step) were also detected. In addition to the statistical methods applied by SAG, RO used its own analysis method and cutoff values from all data sets to compare each of them with a reference in vitro toxicogenomics DB. This proprietary DB contained 17 known toxic compounds tested on rat hepatocytes, including an independent exposure to MP under slightly different experimental conditions. For three of the data sets (BA, BI, RO), the gene expression profiles allowed the correct identification of MP as the best match in the DB, independently of the site where the experiment was performed.

Next, we investigated the influence of the use of different data analysis strategies to identify altered genes on the same data set. The individual analysis methods are described in Table 2, including differences in the definition of cutoff values for parameters such as fold change or p-value. The arbitrary choice of these cutoff values is not trivial and greatly influences the outcome of the analysis. On the one hand, stringent cutoff values lead to a smaller false-positive rate and a high false-negative rate (or low power). This approach can be recommended if each single gene will be interpreted and discussed regarding safety assessment. However, important signals might be missed because relatively small changes in expression may be of high biologic and toxicologic relevance. On the other hand, less stringent filtering criteria cause a high number of false positives but ensure that no relevant genes will remain undetected. In our case, BA and SAG used stringent statistical approaches (t-test with p-value < 0.01, fold change > 1.5 fold), whereas BI and RO used smaller fold changes as cutoff criteria (1.2-fold or 1.25-fold, respectively). As expected, BA and SAG detected fewer regulated genes than did BI and RO (Figure 4, Table 2). For BI the obtained gene list was used as a first-pass filter for the comparison with in-house defined marker genes or for hypothesis generation with a subsequent in-depth analysis of selected genes. When all companies analyzed their own data with their own methods, only 14 probe sets were considered deregulated by all the users in all experiments, and an additional 103 were detected by three of the four laboratories (Figure 5). This demonstrates that an additional layer of complexity and a source of differing interpretation originate from different statistical analysis methods.

The gene changes observed after 24 hr of incubation with the test compound might not be ideal to elucidate the primary events (cause) that trigger the hepatotoxicity of MP. However, the elucidation of downstream gene expression changes, indicative of general cellular dysfunction as a consequence of MP toxicity is valuable as a possible predictor for hepatotoxicity. The identity of the genes that were found changed in at least three of four laboratories (117 genes) represent biologically relevant processes that are obviously affected by MP. Several genes involved in amino acid and nucleotide metabolism were down-regulated. Also, the expression of genes that play a role in the cell cycle and/or apoptosis was changed by MP. Among them, the mitogen-activated protein kinase 6 and ornithine decarboxylase antizyme inhibitor were up-regulated, whereas ectonucleotide pyrophosphatase/phosphodiesterase 2 and insulin growth factor-binding protein were down-regulated. These signals appear contradictory because those genes promoting cell proliferation are not regulated in the same direction. However, the detected changes were generally consistent across users, increasing the confidence in the findings. Another affected pathway involved genes related to the glutathione homeostasis. Ratra et al. (2000) showed that the levels of reduced glutathione are increased to 140% of the control after administration of MP to male Han:Wistar rats. In agreement with this, our experiments show that MP had a substantial effect on genes involved in glutathione metabolism (5-oxoprolinase) and glutathione conjugation (glutathione S-transferase 3 and Yb). Also, other genes involved in detoxification, such as L-gulono-gamma-lactone oxidase and sulfotranferase family 1A were down-regulated. MP also seems to have an effect on the energy balance of the liver. Many genes in the glycolysis pathway and several genes involved in mitochondrial function were down-regulated by the treatment. This finding is also in agreement with previous results obtained in vivo and in vitro. It has been described that MP leads to a significant increase in mitochondria of periportal hepatocytes in rats (Reznik-Schuller and Lijinski 1981). Also, MP caused mitochondrial dysfunction, as detected by mitochondrial swelling, significant losses of ATP, and loss of mitochondrial calcium homeostasis in cultured hepatocytes (Ratra et al. 1998). In addition to the metabolic and energy impairment responses, MP elicits a stress response in the hepatocytes. Reactive oxygen producing systems are repressed, and stress-response genes are up-regulated. This is indicative of the oxidative stress produced by MP (Ratra et al. 1998) and was also described using gene expression profiles of livers of rats treated with MP (Waring et al. 2004). We observed the up-regulation of the ribosome associated membrane protein 4, which belongs to a family consisting of several ribosome associated membrane protein sequences that are known to stabilize membrane proteins in response to stress (Yamaguchi et al. 1999). Also, the myeloid differentiation primary response gene 116 (Gadd34), whose overexpression promotes apoptosis (Hollander et al. 2003), was detected as induced. The Gadd family is known to be up-regulated upon cellular stress and was strongly up-regulated by MP after in vivo exposure (Waring et al. 2004). Because we analyzed the toxicity of MP in isolation, we cannot determine which of these gene changes are specific to MP or might be regulated by other compounds. Also, most of the gene-by-gene changes described occurred at the high concentration, concomitant with slight cytotoxicity. However, some of the differentially expressed genes were also detected at the low dose by some laboratories. It was dear from the clustering data that both RO and SAG could not separate the low dose from the untreated samples. Gene expression data from BA and BI, however, showed that > 25% of the genes were already detectable at the low concentration (Table 4). These two laboratories did not perform a Percoll purification step during the hepatocyte isolation procedure. This interesting finding led us to the hypothesis that in the presence of additional cell types not eliminated by a Percoll purification step (e.g., Kupffer cells or damaged hepatocytes), gene expression changes occur already at concentrations that do not show an effect on the viability of the cells. Further experiments with controlled cell compositions should be performed to clarify this point and define the best-suited in vitro system in terms of sensitivity.

Our results show that several factors from experimental conditions to statistical data analysis contribute to the interlaboratory variability observed for gene expression results. Our data and other published results (Harries et al. 2001; Waring et al. 2001) show that in vitro assays coupled with microarray analysis are useful for detection of hepatotoxicity and mechanistic elucidation of cellular events related to it. This applies best when the experimental and analytical variability is reduced to a minimum, which cannot always be ensured. However, we were able to show that using suitable statistical analysis tools, we could, despite the experimental variability, uncover the commonalities among the experiments. We demonstrated that using a subset of deregulated genes for the analysis, the effects of a high concentration of MP on the cells supersede the interlaboratory variability and that this variability does not mask clear treatment-dependent effects. This finding agrees with a similar analysis performed in vivo (Waring et al. 2004) and also held true when we compared the data obtained at several sites with one in vitro toxicogenomics DB. The encouraging outcome of the comparison with an independent DB is pivotal and indicates that gene expression profiles have the potential to be used as a diagnostic tool for toxicology. However, it is also clear from the presented results that the differences between laboratories make the gene-by-gene comparison of gene expression data from different sources very difficult. This task can be undertaken only with sound statistical tools that allow a relevant subset of genes to be selected.

From a mechanistic point of view, it is important to note that there was good concordance among all users regarding the affected biologic processes, as shown in Table 4. Most of the consistently regulated genes play a role in detoxification/metabolism, processes of growth and death control, immune response, stress, and transport. This indicates that the interpretation of the data from different sources leads to similar conclusions in terms of toxicity and underlying mechanisms despite the differences in number and identity of genes and in the intensity of the regulation.

In summary, our data show that both experimental and statistical variability are important sources of different outcomes between laboratories. To minimize the experimental variation, it is advisable to perform the cell culture and microarray experiments whenever possible at the same experimental site. This is not always possible because often experimental protocols need to be transferable. In these cases, suitable and robust statistical analyses help overcome the differences. Also, we showed that cellular mechanisms involved in MP toxicity can be consistently detected, as illustrated by the gene expression changes listed in Table 4. In addition the positive outcome of the comparison with an in vitro DB underlines that microarray analyses of in vitro systems are robust and can be predictive of toxicity. Whether the involved cellular pathways are specific for MP and are causal to the toxicity in vitro and/or in vivo requires further investigations.

We thank S. Koehl (Boehringer Ingelheim), C. Kneilmann (Boehringer Ingelheim), G. Wasinska-Kempka (Bayer), G. Gehrmann (Schering), M. Jarzombek (Schering), N. Schaub (Hoffmann-La Roche), and E. Durr (Hoffmann-La Roche) for performing the rat hepatocyte experiments. Our special thanks go to M. Thiel (Bayer) and S. Patkovic (Schering) for their skillful assistance with the microarray analyses.

REFERENCES

Baker VA, Harries HM, Waring JF, Duggan CM, Ni HA, Jolly RA, et al. 2004. Clefibrate-induced gene expression changes in rat liver: a cross laboratory analysis using membrane cDNA arrays. Environ Health Perspect 112:428-438.

Boess F, Karnber M, Rorner S, Gasser R, Muller D, Albertini S, et al. 2003. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for texicogenomics use of in vitro systems. Toxicol Sci 73:386-402.

Chu T-M, Deng S, Wolfinger R, Paules RS, Hamadeh HK. 2004. Cross-site comparison of gene expression data reveals high similarity. Environ Health Perspect 112:449-455.

Gomez-Lechon M J, Montova A, Lopez P, Donato T, Larrauri A, Castell JV. 1988. The potential use of cultured hepatocytes in predicting the hepatotoxicity of xenobiotics. Xenobiotica 18:725-735.

Hamadeh HK, Knight BL, Haugen AC, Sieber S, Amin RP, Bushel PR, et al. 2002. Methapyrilene toxicity: anchorage of pathologic observations to gene expression alterations. Toxicol Patho130:470-482.

Harries HM, Fletcher ST, Duggan CM, Baker VA. 2001. The use of genomics technology to investigate gene expression changes in cultured human liver cells. Toxicol In Vitro 15:399-405.

Hollander MC, Poola-Kella S, Fornace AJ. 2003. Gadd 34 functional domains involved in growth suppression and apoptosis. Oncogene 22:3827-3832.

Kilbey BJ, Legator M, Nicholson W, Rarnel C. 1984. Handbook of Mutagenicity ]est Procedures. 2nd ed. Arnsterdarn:EIsevier.

Lee ML, Kun FC, Whitmore GA, Skier J. 2000. Importance of replication in microarray gene expression studies: statistical methods and evidence from repetitive cDNA hybridizations. Proc Natl Acad Sci USA 97:9834-9839.

Lijinski W, Reuber MD, Blackwell BN. 1980. Liver tumors induced in rats by oral administration of the antihistaminic methapyrilene hydrochloride. Science 209:817-819.

Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS. 1996. Expression monitoring by hybridization to highdensity oligonucleotide arrays. Nat Biotechnol 14:1675-1080.

Mirsalis JC. 1987. Genotoxicity, toxicity, and carcinogenicity of the antihistamine rnethapyrilene. Mutat Res 185:309-317.

Noguchi S, Inukai T, Kuno T, Tanaka C. 1992. The suppression of olfactory bulbectorny-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking. Physiol Behav 51:1123-1127.

Paillard F, Finot F, Mouche I, Prenez A, Vericat JA. 1999. Use of primary cultures of rat hepatocytes to predict toxicity in the early development of new chemical entities. Toxicol In Vitro 13:093-700.

Pennie W, Pettit SD, Lord PG. 2004. Toxicogenomics in risk assessment: an overview of an HESI collaborative research program. Environ Health Perspect 112:417-419.

Ratra GS, Morgan WA, Mullervy J, Powell CJ, Wright MC. 1998. Methapyrilene hepatotoxicity is associated with oxidative stress, mitochondrila disfunction and is prevented by the [Ca.sup.2+] channel blocker verapamil. Toxicology 130:79-93.

Ratra GS, Pnwell C J, Park BK, Maggs JL, Cottrell S. 2000. Methapyrilene hepatotoxicity is associated with increased hepatic glutathione, the formation of glucuronide conjugates, and enterohepatic recirculation. Chem Biol Interact 129:279-295.

Reznik-Schuller HM, Lijinski W. 1981. Morphology of early changes in liver carcinogenesis induced by methapyrilene. Arch Toxicn149:79-83.

Robinson D, Pettit S, Morgan DG. 2003. Use of genomics in mechanism based risk assessment. In: Toxicogenornics (Inoue T, Pennie WD, eds). Tokyo:Springer-Verlag, 194-203.

Seglen PO. 1972. Preparation of rat liver cells. Exp Cell Res 74:450-454.

Steinmetz KL, Tyson CK, Meierhenry EF, Splading JW, Mirsalis JC. 1988. Examination of genotoxicity, toxicity and morphologic alterations in hepatocytes following in vivo or in vitro exposure to methapyrilene. Carcinogenesis 9:959-963.

Ulrich RG, Rockett JC, Gibson GG, Pettit SD. 2004. Overview of an interlaboratory collaboration on evaluating the effects of model hepatotoxicants on hepatic gene expression. Environ Health Perspect 112:423-427.

Waring JF, Ciurlionis R, Jolly RA, Heindel M, Ulrich RG. 2001. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol Lett 120:359-368.

Waring JF, Ulrich RG, Flint N, Marfitt D, Kalkuhl A, Staedtler F, et al. 2004. Interlaboratory evaluation of rat hepatic gene expression changes induced by methapyrilene. Environ Health Perspect 112:439-448.

Welch BL. 1938. The significance of the difference between means when the population variances are unequal Biometrika 29:350-362.

Yamaguchi A, Hori O, Stren DM, Hartrnann E, Ogawa S, Tohyama M. 1999. Stress-associated endnplasrnic reticulum protein 1 (SERP1)/ribosome-associated membrane protein 4 (RAMP4) stabilizes membrane proteins during stress and facilitates subsequent glycosylation. J Cell Bio1147:1195-1204.

Johanna M. Beekman, (1) Franziska Boess, (2) Heinrich Hildebrand, (3) Arno Kalkuhl, (4) and Laura Suter (2)

(1) Schering AG, Berlin, Germany; (2) F. Hoffmann-La Roche Ltd., Basel, Switzerland; (3) Bayer HealthCare AG, Wuppertal, Germany;

(4) Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany

The authors declare they have no competing financial interests.

Address correspondence to J.M. Beekman, Schering AG, Global Pharmacogenomics, Muellerstrasse 170-178, 13342 Berlin, Germany. Telephone: [phone]. Fax: [phone]. E-mail: [e-mail]

Received 11 January 2005; accepted 11 August 2005.

Table 1. Sample preparation methods and data analysis tools used by
the contributing companies.

Analysis    Viability       Cell                               RNA
site         (%) (a)    purification   LDH assay            extraction

BA         85, 90, 89   None           Hitachi 717/Roche    RNeasy
BI         81, 74, 73   None           Hitachi 917/Roche    RNeasy (+
                                                            Prot. K)
RO         87, 92, 90   Percoll        ADVIA 1650/LDH       RNAzol/Bio
                                       P-L Bayer            101
SAG        84, 84, 72   Percoll        Hitachi/SYS1 Roche   RNeasy

                                 Data
Analysis                     condensation/       Data analysis
site             IVT         normalization       tools/software

BA         Enzo-Affymetrix   MAS 5.0             Expressionist
BI         Enzo-Affymetrix   MAS 5.0             SAS
RO         Ambion            MAS 5.0             In-house software
SAG        Enzo-Affymetrix   In-house software   Expressionist

Abbreviations: Enzo-Affymetrix, Enzo Diagnostics Inc. and Affymetrix,
Inc.; IVT, in vitro transcription; Prot. K, proteinase K.

(a) Cell viability of the hepatocyte preparations in the main study
(n =3).

Table 2. Number of genes regulated by MP of the BI experiments
calculated by the four different laboratories according to their
applied method.

Treatment        BA            BI               RO             SAG

Low-dose         75           1,296             687            84
High-dose       211           1,914           1,011           289
Union           256           2,486           1,286           332
Method      MAS 5.0        MAS 5.0         MAS 5.0          In-house
            Welch's Mest   Mann-Whitney    Paired t-test,   software
            p<0.01         U-test p<0.05   p<0.1            t-test
Cutoff      > 1.5-fold     > 1.2-fold      >1.25-fold       p<0.01
            change         change          change           >1.5-fold
                                                            change

Table 3. Intersections between the genes regulated by MP per laboratory
calculated by its own methods (values in brackets are percentage of
that company's genes shared with the respective other companies).

Company   BA (%)       BI (%)        RO (%)    SAG (%)

BA        185          138 (6)       84 (8)     16 (13)
BI        138 (75)   2,486          579 (53)    82 (65)
RO         84 (45)     579 (23)   1,085         74 (59)
SAG        16 (9)       82 (3)       74 (7)    126

Table 4. Genes regulated by a low or high dose of MP detected by at
least three of the four laboratories.

Affymetrix                                              BA
probe set ID (a)   Gene description (a)      20 [micro]M   100 [micro]M

Amino acid
metabolism
 AB003400_at       o-amino acid oxidase       -1.29         -2.13 (b)
 AF038870_at       beta ine-homocysteine      -2.28 (b)     -5.02 (b)
                   methyltransferase
 D17370_at         CTL target antigen         -1.27         -2.32 (b)
 D87839_g_at       4-aminobutyrate            -2.22 (b)     -4.81 (b)
                   aminotransferase
 J02827_g_at       branched chain alpha-      -1.54         -1.45
                   ketoacid dehydrogenase
                   subunit Et alpha
 M88347_s_at       cystathionine beta         -1.50         -2.44 (b)
                   synthase
 U68168_at         kynureninase               -2.12 (b)     -5.46 (b)
                   (L-kynurenine
                   hydrolase)

Cell-cycle/
apoptosis
AB002086_at        p47 protein                 1.21          1.35
AF020618_g_at      myeloid differentiation     2.05 (b)      4.71 (b)
                   primary response gene
                   116
D28560_at          ectonucleotide             -1.22         -2.01 (b)
                   pyrophosphatase/
                   phosphodiesterase 2
D28560_g_at        ectonucleotide             -1.67 (b)     -2.43 (b)
                   pyrophosphatase/
                   phosphodiesterase 2
rc_Al043631_s_at   ornithine decarboxylase     1.67 (b)      2.75 (b)
                   antizyme inhibitor
S46785_at          insulin-like growth         1.03         -1.10
                   factor binding protein
                   complex acid-labile
                   subunit

Detoxification
 D14564cds_s_at    L-gulono-gamma-lactone     -1.32         -1.49
                   oxidase (BLAST)
 J03914cds_s_at    glutathione                -1.39         -1.92 (b)
                   S-transferase Yb
                   subunitgene
 L19998_at         sulfotransferase family    -1.93         -4.14
                   1A, phenol-preferring,
                   member 1
 L19998_g_at       sulfotransferase family    -1.71         -3.36
                   1A, phenol-preferring,
                   member 1
 M23601_at         monoamine oxidase B        -1.45         -2.40 (b)
 rc_AA892234_at    ESTs, highly similar       -1.46         -2.26 (b)
                   to microsomal GST 3
 U70825_at         5-oxoprolinase             -1.47         -2.30 (b)
                   (ATP-hydrolyzing)

Glycolysis and
gluconeogenesis
 AF062740_at       pyruvate dehydrogenase      1.30          1.69 (b)
                   phosphataseisoenzyme 1
 J05446_at         glycogen synthase 2        -2.00 (b)     -3.33 (b)
                   (liver)
 M12919mRNA#2_at   aldolase A                  1.25          1.55
 M83298_at         protein phosphatase 2,      1.37          1.78 (b)
                   regulatory subunit B, a
                   isoform
 M86240_at         fructose-1,6-              -2.03 (b)     -2.55 (b)
                   bisphosphatase 1
 rc_AA892395_s_at  aldolase B                 -2.12         -3.59
 rc_AA945442_at    glucokinase regulatory     -1.67 (b)     -2.06 (b)
                   protein
 S79213_at         phosphataseinhibitor-2      1.57 (b)      2.11 (b)
 U32314_g_at       pyruvate carboxylase       -1.55 (b)     -1.62 (b)
 X02291exon_s_at   aldolase B (BLAST)         -1.58         -2.24
 X53428cds_s_at    glycogen synthase           1.52 (b)      1.82 (b)
                   kinase 3 beta
 X73653_at         glycogen synthase           1.32          1.67 (b)
                   kinase 3 beta

Immune response
 AF029240_g_at     BM1 k MHC class Ib         -1.61         -1.54
                   antigen, strain SHR
 L12025_at         tumor-associated            2.15 (b)      3.43 (b)
                   glycoprotein pE4
 U47031_at         purinergic receptor        -1.14         -1.13
                   P2X, ligand-gated ion
                   channel

Mitochondrial
function
 AF062740_at       pyruvate dehydrogenase      1.30          1.69 (b)
                   phosphatase isoenzyme 1
 D00569_g_at       2,4-dienoyl CoA            -1.39         -1.63 (b)
                   reductase 1,
                   mitochondrial
 D30740_at         14-3-3 protein mBNA for     1.32          1.51 (b)
                   mitochondrial import
                   stimulation factor
                   (MSF) S1 subunit
 J05029_s_at       acylcoenzyme A             -1.02         -1.25
                   dehydrogenase,long
                   chain
 J05030_at         acyl coenzyme A            -1.27         -1.54 (b)
                   dehydrogenase, short
                   chain
 M23601_at         monoamine oxidase B        -1.45         -2.40 (b)
 M33648_at         mitochondrial              -4.16 (b)    -11.38 (b)
                   3-hydroxy-3-
                   methylglutaryl-CoA
                   synthase
 M33648_g_at       mitochondrial3-hydroxy-    -2.40 (b)     -7.85 (b)
                   3-methylglutaryl-
                   Co Asynthase
 rc_AA817846_at    ESTs, highly similar to    -1.95         -3.25
                   BDH RAT o-beta-hydroxy
                   butyrate dehydrogenase
 rc_A1176422_at    ESTs, highly similar to    -1.22         -1.53
                   541115 probable
                   flavoprotein-ubiquinone
                   oxidoreductase
 U32314_g_at       pyruvate carboxylase       -1.55         -1.62
 Y12635_at         ATPase, H'                  1.40          2.43 (b)
                   transporting,
                   lysosomal, isoform 2

Nucleotide
metabolism
 D28560_at         ectonucleotide             -1.22         -2.01 (b)
                   pyrophosphatase/
                   phosphodiesterase 2
 D28560_g_at       ectonucleotide             -1.67 (b)     -2.43 (b)
                   pyrophosphatase/
                   phosphodiesterase 2
 M97662_at         ureidopropionase, beta     -1.93         -3.08
 rc_AA799402_at    ESTs, weakly similar to    -1.10         -1.93
                   S18140 hypoxanthine
                   phosphoribosyl-
                   transferase

Protein
metabolism
 AF100470_g_at     ribosome associated         1.11          1.30
                   membrane protein 4
 L38482-g_at       serine protease gene        1.11          1.29
 M96633_at         mitochondrial              -1.48         -2.45 (b)
                   intermediate peptidase
 rc_AA892831_s_at  ESTs, highly similar to     1.12          1.28
                   JC6524 26S proteasome
                   regulatory complex
                   chain p44.5
 X70900_at         hepsin                     -1.59 (b)     -2.45 (b)

Signal
transduction
 AF036537-g_at     homocysteine respondent     1.56          1.67
                   protein HCYP2
 AF076619_at       growth factor receptor     -1.11         -1.67 (b)
                   bound protein 14
 L14323_at         phospholipase C-betal      -1.27         -2.03 (b)
 M64301_g_at       mitogen-activated           1.26          2.17 (b)
                   protein kinase 6
 M83298_at         protein phosphatase 2       1.37          1.78 (b)
                   (formerly 2A),
                   regulatory subunitB
                   (PR 52), alpha isoform
 rc_AA891580_at    ESTs, highly similar to     1.27          1.61 (b)
                   cylindromatosis (turban
                   tumor syndrome);
                   cylindromatosis 1
 rc_A1070721_s_at  glial cell line derived    -2.49         -2.68
                   neurotrophic factor
                   family receptor
                   [alpha]1
 rc_A1171630_s_at  p38 mitogen activated      -1.21         -1.70 (b)
                   protein kinase

Stress response
 M23601_at         monoamme oxidase B         -1.45         -2.40 (b)
 M86389cds_s_at    heat shock 27 kDa           1.65          2.15
                   protein
 rc_AA891286_at    thioredoxin reductase 1     1.45          1.78 (b)
 rc_AI171630_s_at  p38 mitogen activated      -1.21         -1.70 (b)
                   protein kinase
 rc_aI179610_at    heme oxygenase              1.34          3.37 (b)

Transcription
 ABO12230_at       NF1-B1                     -1.20         -1.86 (b)
 AF003926_at       nuclear receptor           -1.24         -1.69 (b)
                   subfamily 2, group F,
                   member 6
 AF016387_g_at     retinoid X receptor        -1.31         -2.15 (b)
                   gamma

Transport
 ABO15433_s_at     solute carrier family       1.36          1.89 (b)
                   3, member 2
 U72741_gat        lectin, galactose          -1.37         -1.46
                   binding, soluble 9
                   (galectin-9)
 Z36944cds_at      putative chloride          -1.88 (b)     -2.50 (b)
                   channel (similar to Mm
                   CIcn4-2)

                              BI                     RO
Affymetrix             20          100          20         100
probe set ID (a)    [micro]M     [micro]M    [micro]M   [micro]M

Amino acid
metabolism
 AB003400_at        -1.96 (b)    -3.35 (b)   -1.22      -1.89 (b)
 AF038870_at        -4.41 (b)    -7.21 (b)   -1.23      -2.04 (b)
 D17370_at          -1.50 (b)    -2.58 (b)    1.17      -1.43 (b)
 D87839_g_at        -2.34 (b)    -8.16 (b)   -1.54 (b)  -5.00 (b)
 J02827_g_at        -1.46 (b)    -1.59 (b)   -1.18      -1.35 (b)
 M88347_s_at        -1.60 (b)    -2.81 (b)   -1.23      -2.44 (b)
 U68168_at          -2.36 (b)    -6.22 (b)   -1.28 (b)  -4.17 (b)

Cell-cycle/
apoptosis
AB002086_at          1.37 (b)     1.56 (b)    1.26 (b)   1.60 (b)
AF020618_g_at        1.82 (b)     5.25 (b)    1.21       3.88 (b)
D28560_at           -1.65 (b)    -3.24 (b)   -1.22      -2.04 (b)
D28560_g_at         -3.11 (b)    -9.83 (b)   -1.28 (b)  -2.27 (b)
rc_Al043631_s_at     2.72 (b)     4.25 (b)    1.29       2.90 (b)
S46785_at           -1.41 (b)    -1.69 (b)   -1.20      -1.79 (b)

Detoxification
 D14564cds_s_at     -2.05 (b)    -2.50 (b)   -1.20      -2.17 (b)
 J03914cds_s_at     -1.43 (b)    -1.93 (b)   -1.14      -1.41 (b)
 L19998_at          -5.86 (b)    -9.35 (b)   -1.59 (b)  -8.33 (b)
 L19998_g_at        -5.97 (b)    -6.94 (b)   -1.59 (b)  -6.25 (b)
 M23601_at          -2.07 (b)    -4.65 (b)   -1.06      -2.44 (b)
 rc_AA892234_at     -1.55 (b)    -3.54 (b)   -1.33 (b)  -2.33 (b)
 U70825_at          -1.95 (b)    -5.46 (b)   -1.23      -3.33 (b)

Glycolysis and
gluconeogenesis
 AF062740_at        -1.42 (b)     1.37 (b)   -1.04       1.31 (b)
 J05446_at          -2.35 (b)    -5.92 (b)   -1.19      -2.86 (b)
 M12919mRNA#2_at     1.30 (b)     1.84 (b)   -1.01       1.76 (b)
 M83298_at           1.61 (b)     2.18 (b)    1.09       1.46 (b)
 M86240_at          -2.14 (b)    -3.15 (b)   -1.24      -2.70 (b)
 rc_AA892395_s_at   -1.73 (b)    -4.84 (b)   -1.09      -2.78 (b)
 rc_AA945442_at     -1.38 (b)    -2.02 (b)   -1.30      -1.61 (b)
 S79213_at           2.00 (b)     2.48 (b)    1.20       1.39 (b)
 U32314_g_at        -2.28 (b)    -4.61 (b)   -1.06      -1.52 (b)
 X02291exon_s_at    -1.39 (b)    -3.00 (b)   -1.08      -2.17 (b)
 X53428cds_s_at      2.12 (b)     2.78 (b)    1.08       2.41 (b)
 X73653_at           1.99         2.42        1.03       1.87 (b)

Immune response
 AF029240_g_at      -1.63 (b)    -2.42 (b)   -1.20      -1.82 (b)
 L12025_at           2.59 (b)     5.30 (b)    1.19       3.03 (b)
 U47031_at          -1.21 (b)    -1.36 (b)   -1.14      -1.56 (b)

Mitochondrial
function
 AF062740_at        -1.42         1.37 (b)   -1.04       1.31 (b)
 D00569_g_at        -1.11        -2.07 (b)   -1.18      -1.64 (b)
 D30740_at           1.56 (b)     1.78 (b)    1.17       1.29 (b)
 J05029_s_at        -1.43 (b)    -1.98 (b)   -1.09      -1.79 (b)
 J05030_at          -1.62 (b)    -1.63 (b)   -1.10      -1.82 (b)
 M23601_at          -2.07 (b)    -4.65 (b)   -1.06      -2.44 (b)
 M33648_at          -2.92 (b)   -13.51 (b)   -1.30      -6.25 (b)
 M33648_g_at        -2.46 (b)   -10.44 (b)   -1.25 (b)  -4.55 (b)
 rc_AA817846_at     -3.32 (b)    -8.04 (b)   -1.41      -5.00 (b)
 rc_A1176422_at     -1.61 (b)    -2.36 (b)   -1.19      -1.30 (b)
 U32314_g_at        -2.28 (b)    -4.61 (b)   -1.06      -1.52 (b)
 Y12635_at           1.51 (b)     2.74 (b)    1.15       2.18 (b)

Nucleotide
metabolism
 D28560_at          -1.65 (b)    -3.24 (b)   -1.22      -2.04 (b)
 D28560_g_at        -3.11 (b)    -9.83 (b)   -1.28 (b)  -2.27 (b)
 M97662_at          -2.99 (b)    -4.56 (b)   -1.43 (b)  -3.13 (b)
 rc_AA799402_at     -1.79 (b)    -1.67 (b)   -1.27      -1.27 (b)

Protein
metabolism
 AF100470_g_at       1.29 (b)     1.41 (b)    1.18       1.61 (b)
 L38482-g_at         1.20 (b)     1.09        1.11       1.40 (b)
 M96633_at          -1.74 (b)    -3.47 (b)   -1.23      -2.22 (b)
 rc_AA892831_s_at    1.44 (b)     1.32 (b)    1.09       1.50 (b)
 X70900_at          -1.69 (b)    -2.56 (b)   -1.23      -1.96 (b)

Signal
transduction
 AF036537-g_at       1.83 (b)     1.85 (b)    1.38 (b)   2.18 (b)
 AF076619_at        -1.09        -2.23 (b)   -1.08      -1.79 (b)
 L14323_at          -1.55 (b)    -3.34 (b)    1.06       1.67 (b)
 M64301_g_at         1.06         2.51 (b)   -1.06       1.62 (b)
 M83298_at           1.61 (b)     2.18 (b)    1.09       1.46 (b)
 rc_AA891580_at      1.90 (b)     2.02 (b)    1.27 (b)   1.32
 rc_A1070721_s_at   -1.19        -2.15 (b)   -1.32      -2.77 (b)
 rc_A1171630_s_at   -1.75 (b)    -2.37 (b)   -1.23      -1.64 (b)

Stress response
 M23601_at          -2.07 (b)    -4.65 (b)   -1.06      -2.44 (b)
 M86389cds_s_at      3.11 (b)     2.24 (b)    1.16       2.22 (b)
 rc_AA891286_at      1.77 (b)     1.85 (b)    1.22       1.66 (b)
 rc_AI171630_s_at   -1.75 (b)    -2.37 (b)   -1.23      -1.64 (b)
 rc_aI179610_at      1.87         3.45        1.18       2.99 (b)

Transcription
 ABO12230_at        -1.03        -2.11 (b)   -1.32 (b)  -1.32
 AF003926_at        -1.03        -1.58 (b)   -1.10      -1.41 (b)
 AF016387_g_at      -1.39 (b)    -2.56 (b)   -1.10      -1.69 (b)

Transport
 ABO15433_s_at       1.96 (b)     3.30 (b)    1.18       1.77 (b)
 U72741_gat         -2.28 (b)    -3.44 (b)   -1.23      -1.49 (b)
 Z36944cds_at       -1.57 (b)    -1.93 (b)   -1.12      -2.13 (b)

                           SAG             Direction
Affymetrix             20         100        of
probe set ID (a)    [micro]M   [micro]M    change

Amino acid
metabolism
 AB003400_at        -1.06      -1.52       Down
 AF038870_at         1.20      -1.62       Down
 D17370_at           1.04      -1.57       Down
 D87839_g_at        -1.09      -2.64 (b)   Down
 J02827_g_at         1.03      -1.80 (b)   Down
 M88347_s_at        -1.29      -1.29       Down
 U68168_at          -1.08      -2.30 (b)   Down

Cell-cycle/
apoptosis
AB002086_at          1.23       1.66 (b)   Up
AF020618_g_at       -1.06       2.55 (b)   Up
D28560_at           -1.15      -2.28       Down
D28560_g_at         -1.24      -2.11       Down
rc_Al043631_s_at    -1.04       2.26       Up
S46785_at            1.67 (b)   1.00       Down

Detoxification
 D14564cds_s_at     -1.04      -1.78 (b)   Down
 J03914cds_s_at     -1.01      -1.66 (b)   Down
 L19998_at          -1.21      -6.39 (b)   Down
 L19998_g_at        -1.17      -5.14 (b)   Down
 M23601_at          -1.04      -2.08 (b)   Down
 rc_AA892234_at     -1.02      -2.18       Down
 U70825_at          -1.14      -2.05       Down

Glycolysis and
gluconeogenesis
 AF062740_at         1.32       1.39       Up
 J05446_at           1.05      -2.11       Down
 M12919mRNA#2_at     1.11       1.72 (b)   Up
 M83298_at          -1.07       1.32       Up
 M86240_at          -1.02      -2.32 (b)   Down
 rc_AA892395_s_at    1.01      -2.37 (b)   Down
 rc_AA945442_at     -1.18      -1.88 (b)   Down
 S79213_at          -1.09       1.30       Up
 U32314_g_at        -1.08      -1.30       Down
 X02291exon_s_at    -1.06      -2.03 (b)   Down
 X53428cds_s_at      1.01       2.60       Up
 X73653_at           1.09       2.72 (b)   Up

Immune response
 AF029240_g_at      -1.18      -2.09 (b)   Down
 L12025_at          -1.02       1.81       Up
 U47031_at          -1.09      -1.62 (b)   Down

Mitochondrial
function
 AF062740_at         1.32       1.39       Up
 D00569_g_at        -1.05      -1.42       Down
 D30740_at           1.08       1.30       Up
 J05029_s_at        -1.08      -1.54 (b)   Down
 J05030_at           1.01      -1.58       Down
 M23601_at           1.04      -2.08 (b)   Down
 M33648_at          -1.06      -2.93 (b)   Down
 M33648_g_at         1.00      -2.02       Down
 rc_AA817846_at     -1.07      -2.58 (b)   Down
 rc_A1176422_at     -1.03      -1.79 (b)   Down
 U32314_g_at        -1.09      -1.30       Down
 Y12635_at           1.04       1.81       Up

Nucleotide
metabolism
 D28560_at          -1.15      -2.28       Down
 D28560_g_at        -1.24      -2.11       Down
 M97662_at          -1.10      -4.08 (b)   Down
 rc_AA799402_at     -1.11      -1.59 (b)   Down

Protein
metabolism
 AF100470_g_at       1.07       1.57 (b)   Up
 L38482-g_at         1.09       1.78 (b)   Up
 M96633_at           1.08      -1.77       Down
 rc_AA892831_s_at    1.05       1.84 (b)   Up
 X70900_at           1.02      -2.56 (b)   Down

Signal
transduction
 AF036537-g_at      -1.16       1.95 (b)   Up
 AF076619_at        -1.03      -1.35       Down
 L14323_at          -1.05      -1.33       Down
 M64301_g_at        -1.04       1.27       Up
 M83298_at          -1.07       1.32       Up
 rc_AA891580_at      1.00       1.30       Up
 rc_A1070721_s_at   -1.07      -1.95 (b)   Down
 rc_A1171630_s_at   -1.10      -1.29       Down

Stress response
 M23601_at          -1.04      -2.08 (b)   Down
 M86389cds_s_at      1.25       2.87 (b)   Up
 rc_AA891286_at      1.12       1.40       Up
 rc_AI171630_s_at   -1.10      -1.29       Down
 rc_aI179610_at      1.12       2.74 (b)   Up

Transcription
 ABO12230_at         1.00       1.00       Down
 AF003926_at        -1.04      -1.41       Down
 AF016387_g_at       1.00       1.00       Down

Transport
 ABO15433_s_at       1.07       1.89       Up
 U72741_gat         -1.06      -1.98 (b)   Down
 Z36944cds_at       -1.09      -1.37       Down

(a) From Affymetrix, Inc.
(http://www.affymetrix.com). (b) Significant fold changes.

Table 5. Comparisons with the Roche in vitro toxicogenomics database.

                                             Similarity index
                 Dose                                 BA
Data set      ([micro]M)   Mechanism         High           Low

MP_BA_high       100       Direct reaction   N/A         28.55 (a)
MP_BA_low         20       Direct reaction   28.55 (a)   N/A
MP_BI_high       100       Direct reaction   28.24 (a)   12.66
MP_BI_ low        20       Direct reaction   24.23       18.46 (a)
MP_RO_high       100       Direct reaction   24.06       11.78
MP_RO_low         20       Direct reaction    4.72        4.95
MP_SAG_high      100       Direct reaction   17.78       15
MP_SAG_low        20       Direct reaction    0.31        0.35
MP_DB_100        100       Direct reaction   22.16 (b)   12.81 (b)
MP_DB_300        300       Direct reaction   20.08 (b)    8.47
Other_cmp        N/A       Direct reaction    2.82        3.74
Other_cmp        N/A       Direct reaction   11.98        8.45
Other_cmp        N/A       Direct reaction   17.93       11.84 (b)
Other_cmp        N/A       Perox. prolif.     < 0         < 0
Other_cmp        N/A       Perox. prolif.     < 0         < 0

                           Similarity index
                       BI                      RO
Data set        High       Low           High       Low

MP_BA_high    28.44 (a)   24.23 (a)   24.06 (a)   4.72
MP_BA_low     12.66       18.46       11.78       4.95
MP_BI_high    N/A         33.44 (a)   26.02 (a)   3.12
MP_BI_ low    33.44 (a)   N/A         21.67       5.51
MP_RO_high    26.02       21.67       N/A         4.95
MP_RO_low      3.12        5.51        6.69       N/A
MP_SAG_high   13.97       21.14       20.29       6.69 (a)
MP_SAG_low     0.00        0.84        1.10       1.06
MP_DB_100     20.95 (b)   19.50 (b)   21.82 (b)   6.69 (a,b)
MP_DB_300     23.21 (b)   12.25       17.51 (b)   3.08
Other_cmp      2.80        4.88        2.57       4.16
Other_cmp     12.65       13.39       11.87       4.35 (b)
Other_cmp     16.3        14.35 (b)   14.33       3.84
Other_cmp      < 0         < 0         < 0        < 0
Other_cmp      < 0         < 0         < 0        0.27

              Similarity index
                       SAG
Data set         High       Low

MP_BA_high    17.78       0.31
MP_BA_low     15.00       0.35
MP_BI_high    13.97       0.00
MP_BI_ low    21.14 (a)   0.84
MP_RO_high    20.29 (a)   1.10
MP_RO_low      6.69       1.06
MP_SAG_high   N/A         3.77 (a)
MP_SAG_low     3.77       N/A
MP_DB_100     15.71 (b)   0.94
MP_DB_300      7.60       0.41
Other_cmp      4.25       2.83 (a,b)
Other_cmp     11.21       1.76 (b)
Other_cmp     10.92       1.14
Other_cmp      0.85       < 0
Other_cmp      0.72       < 0

Abbreviations: N/A, not applicable; Other cmp: other compound in DB;
Perox. prolif., peroxisome proliferators. (a) Top two of comparison
including data sets of this study. (b) Top two of comparison without
data sets of this study.